The International Contract Pharma Association (ICPA) will host India Unlimited 4.0 in San Diego on June 21, 2026, from 2:00 PM to 5:00 PM.

This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing.

The high-level stakeholder meeting aims to position India as a preferred global hub for pharma and biopharma research, development, and manufacturing, while enabling international participants to better understand the country’s expanding ecosystem of opportunities and services.

The event will feature panel discussions and one-on-one interactions with leaders from India’s public and private sectors, including Indian MNCs and international companies.

Focus on innovation and manufacturing

The first session, titled “India increases its Biotech Innovation and Manufacturing Quotient,” will spotlight India’s evolving policy and industry landscape.

A key highlight is the Government of India’s creation of a National R&D Fund, designed to support the research ecosystem over the next five years. The initiative envisions an equal contribution from the private sector, building a $1 billion corpus from government funding matched by industry participation.

The session will also examine how Indian companies are investing heavily in advanced areas such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), cell and gene therapy (CGT), mRNA vaccines, viral-like particles (VLPs), biosimilars, and novel biologics.

The event note emphasizes that Indian pharma majors are increasingly expanding through long-term partnerships, overseas acquisitions, and global subsidiaries, with several biosimilars already making inroads into developed markets.

Global R&D and supply chain partnerships

The second session, “Servicing global Research, Development and Manufacturing needs of international stakeholders,” will focus on India’s role in supporting multinational R&D and supply chains.

With global pharmaceutical and biopharma companies seeking more resilient and efficient supply chains, India is expected to showcase its strengths in historically robust pharmaceutical manufacturing, bio-pharma services, IT, and AI-enabled drug development support.

The discussion will also highlight the growing presence of multinational companies establishing Global Capability Centres (GCCs) across Indian innovation hubs such as Bengaluru, Hyderabad, and Chennai.

According to the organizers, attendance is by registration only and free of cost, with 75 participants to be shortlisted based on defined criteria, and confirmations expected by May 15.

Previous editions of India Unlimited have been held in San Diego (2022 and 2024) and Boston (2025), reflecting sustained international interest in India’s life sciences and biopharma value proposition.

Speaking to the India Pharma Post, Dr Anil Chauhan, Founding Director of ICPA, said, “Currently, the Indian economy is performing well, with a growth rate forecast at around 6%, which is almost double the global average.” The biopharma sector has been growing at a higher rate than the overall pharma sector. Indian companies have done well in the vaccines space and are now trying to replicate that success in other biologics products.”

He added futher, “Keeping recent policies of various countries and global events in view, countries are more inclined to reshore or friend-shore their requirements.” To garner a larger share, countries like India and its important stakeholders need to communicate the opportunities and strengths to their potential clients. These efforts are akin to confidence-building measures. India Unlimited is one such initiative that ICPA began in 2022.”